Krystal Biotech Inc
SWB:4KB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
Krystal Biotech Inc
SWB:4KB
|
US |
|
Magnitogorskiy Metallurgicheskiy Kombinat P.A.O.
MOEX:MAGN
|
RU |
|
V
|
Victory Capital Holdings Inc
F:3PK
|
US |
|
A
|
ADM Hamburg AG
F:OEL
|
DE |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
US |
|
K
|
Krystal Biotech Inc
F:4KB
|
US |
Intrinsic Value
Is 4KB undervalued or overvalued?
See the intrinsic value estimate for Krystal Biotech Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Krystal Biotech Does
Krystal Biotech is a biotechnology company that develops gene therapies for rare diseases, especially inherited skin disorders. Its main product is a topical gene therapy designed to help patients with dystrophic epidermolysis bullosa, a serious condition that makes the skin extremely fragile. The company also works on additional gene therapy programs that use the same core technology.
- Headquarters
- United States of America US
- Employees
- 295
- IPO date
- Sep 20, 2017
Krystal Biotech has a wide economic moat
Patents and regulatory approvals protect Krystal’s specific gene therapy from direct copying, while its ready-made topical treatment avoids the patient-specific cell production and surgical application required by Abeona’s Zevaskyn for recessive DEB. Together, these barriers make Krystal’s treatment harder to reproduce and less resource-intensive to deliver than that rival’s approach.
Read the full moat analysis
Revenue & Expenses Breakdown
Krystal Biotech Inc
Earnings Waterfall
Krystal Biotech Inc
The intrinsic value for Krystal Biotech Inc (4KB) under the Base Case is hidden EUR.
Compared with the current market price of 272.3 EUR, the stock appears hidden.
